Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Hutchison MediPharma"
Count: 94
Selected: 0
| NCT ID | Title |
|---|
| NCT05368805 | Fruquintinib DDI Study With P-gp and BCRP Substrates | ||
| NCT02549937 | A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors | ||
| NCT05216367 | Fruquintinib Hepatic Impairment Study | ||
| NCT05216354 | Fruquintinib Renal Impairment Study | ||
| NCT04814732 | Expanded Access Program of Surufatinib | ||
| NCT05318820 | A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers | ||
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | ||
| NCT04322539 | A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer | ||
| NCT05277454 | Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT | ||
| NCT05176691 | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL | ||
| NCT04579679 | Open-Label Surufatinib in European Patients With NET | ||
| NCT04764474 | A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH | ||
| NCT05173142 | HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors | ||
| NCT05093322 | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | ||
| NCT04762602 | A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations | ||
| NCT03786926 | Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | ||
| NCT05077384 | Open-label Study of Surufatinib in Japanese Patients | ||
| NCT05190068 | HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | ||
| NCT03779113 | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma | ||
| NCT05015608 | Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification | ||
| NCT05009836 | Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC | ||
| NCT02897479 | A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer | ||
| NCT04755088 | Surufatinib Renal Impairment Study | ||
| NCT04755075 | Surufatinib Hepatic Impairment Study | ||
| NCT05015621 | A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma | ||
| NCT04923945 | Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients | ||
| NCT04923932 | Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients | ||
| NCT04169672 | Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors | ||
| NCT04908046 | A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors | ||
| NCT05029635 | Phase III Study on HMPL-523 for Treatment of ITP | ||
| NCT03251378 | A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer | ||
| NCT02589821 | Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors | ||
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Triple Negative Breast Cancer | ||
| NCT04645940 | Fruquintinib Food Effect and Proton Pump Inhibitor Study | ||
| NCT04557397 | Fruquintinib CYP3A Inhibitor and Inducer Study | ||
| NCT04510649 | Surufatinib DDI With a PPI and a CYP3A Inducer | ||
| NCT04849351 | Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma | ||
| NCT04372394 | A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects | ||
| NCT02588170 | Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors | ||
| NCT03223376 | A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) | ||
| NCT04372407 | A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects | ||
| NCT03951623 | The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients | ||
| NCT03903705 | Fruquintinib in Combination With Sintilimab in Patients With Advanced Solid Tumor | ||
| NCT02503033 | A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies | ||
| NCT00659802 | Phase II Study of HMPL-004 in Patients With Ulcerative Colitis | ||
| NCT02133157 | Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors | ||
| NCT04353375 | Phase II Study of HMPL-453 Tartrate in Patients With Advanced Intrahepatic Cholangiocarcinoma With FGFR2 Fusion | ||
| NCT04290325 | HMPL-453 in Advanced Malignant Mesothelioma | ||
| NCT04272957 | A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms | ||
| NCT03231501 | HMPL-813 in Treating Patients With Glioblastoma |
